ClearPoint Neuro (CLPT) to Release Earnings on Tuesday

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 13th. Analysts expect ClearPoint Neuro to post earnings of ($0.15) per share and revenue of $8.21 million for the quarter. ClearPoint Neuro has set its FY 2025 guidance at EPS.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). The business had revenue of $7.77 million for the quarter, compared to analyst estimates of $8.23 million. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Price Performance

Shares of CLPT opened at $13.88 on Tuesday. ClearPoint Neuro has a one year low of $5.11 and a one year high of $19.22. The company has a market cap of $388.36 million, a PE ratio of -20.12 and a beta of 1.03. The stock has a 50-day moving average of $12.86 and a 200-day moving average of $14.20.

Analyst Ratings Changes

Several research analysts recently weighed in on CLPT shares. B. Riley boosted their price target on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. Stifel Nicolaus raised their price target on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Finally, Lake Street Capital upped their price objective on ClearPoint Neuro from $17.00 to $30.00 and gave the company a "buy" rating in a research note on Tuesday, January 21st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.